The main goal of the trial is to find out whether LY4268989 can bring more participants into clinical remission—periods when symptoms are absent or very mild—than the placebo during the first 10 weeks and to see if the benefit continues through a longer, 52‑week maintenance phase for those who respond early. Participants will start by taking the study tablets daily for about ten weeks (the induction phase). If they show improvement, they may continue the same treatment for up to a year (the maintenance phase), with regular visits to check how they are doing.

During the study, doctors will use a scoring system called the Modified Mayo Score to decide whether a person has reached remission; this score looks at stool frequency, bleeding, endoscopic findings, and overall health. “Induction” refers to the initial treatment period aimed at quickly reducing inflammation, while “maintenance” means the ongoing treatment intended to keep the disease under control. Participants will have routine check‑ups, blood tests, and questionnaires to monitor safety and how well the medication works.

The purpose of the study is to assess the safety and tolerability of these treatment regimens. Participants will receive a single injection at the start and then continue receiving additional injections according to a fixed schedule over many months. Regular visits will be scheduled to check health status, and an examination of the intestine using a camera (often called an endoscopy) will be performed around week 48 to see how the lining has responded.

Throughout the trial, researchers will closely watch for any side effects that arise after treatment and will record any new health problems. The endoscopic examination will help determine whether the inner surface of the colon shows signs of healing, providing an indication of how well the medication may be working while ensuring participants remain safe.

People in the study are assigned by chance to receive either inclisiran or placebo, and neither the participants nor the study team knows which one is given. The study follows participants over time while they receive the injections and are checked regularly for major heart-related problems such as myocardial infarction (heart attack), ischemic stroke (stroke caused by a blocked blood vessel), death from heart disease, or urgent procedures to open blocked heart arteries. The main purpose of the study is to find out whether inclisiran lowers the risk of these serious events better than placebo.

The purpose of the study is to see if ziltivekimab works better than placebo in reducing the risk of serious heart-related problems in people who have both cardiovascular disease and kidney disease along with signs of inflammation in their body. The main focus is on preventing major cardiovascular events, which include death from heart-related causes, non-fatal heart attack, and non-fatal stroke. A heart attack occurs when blood flow to part of the heart muscle is blocked, while a stroke happens when blood flow to part of the brain is interrupted.

During the study, participants will receive either ziltivekimab or placebo through regular injections while continuing their standard medical treatment. The study will track various health outcomes over time, including heart attacks, strokes, heart-related deaths, hospital admissions for heart problems, and changes in kidney function. Researchers will also monitor changes in inflammation markers in the blood, heart function measurements, and overall health status. The study will measure how the kidneys are working by looking at blood test results that show the filtering ability of the kidneys and the amount of protein in the urine, which can indicate kidney damage.

The purpose of this study is to determine if NBI-1065845 is effective and safe compared to placebo when used as an additional treatment for people with moderate to severe depression. Participants in this study will continue taking their regular antidepressant medication while also receiving either the study drug or placebo.

The study will monitor changes in depression symptoms over an 8-week period. Participants will need to attend regular appointments for evaluations of their depression symptoms using standardized rating scales that measure the severity of depression and how it affects daily functioning.

Participants in the study will receive Dexpramipexole in the form of a film-coated tablet, which is taken orally. Some participants may receive a placebo, which looks like the medication but does not contain the active ingredient. The study will also involve other medications commonly used for asthma, such as Salbutamol and Budesonide/Formoterol, which are administered through inhalation. These medications help to open the airways and reduce inflammation, making it easier to breathe.

The trial will last for one year, during which participants will be monitored regularly to assess the safety and effectiveness of Dexpramipexole in managing severe eosinophilic asthma. The goal is to determine if this medication can help reduce the frequency and severity of asthma attacks, improve lung function, and enhance the overall quality of life for those affected by this condition.

The purpose of this study is to find out if ziltivekimab works better than placebo in reducing the risk of death from heart and blood vessel problems and preventing heart failure events such as hospital stays or urgent visits for worsening heart failure. The study will also look at other health outcomes including the combined risk of death from heart problems, heart attacks, and strokes, as well as how the treatment affects kidney function, quality of life, and inflammation levels in the body. Quality of life will be measured using questionnaires that ask about symptoms and daily activities.

During the study, participants will receive monthly injections for up to 48 months. The study will track various health events including hospitalizations for heart failure, deaths, heart attacks, strokes, and changes in heart and kidney function. Blood tests will be done to measure inflammation markers like hs-CRP and heart stress markers like NT-proBNP. Heart function will be checked using echocardiography, which is an ultrasound test that creates pictures of the heart. The study will continue until enough information has been collected to determine whether ziltivekimab is effective in helping people with this type of heart failure and inflammation.

The purpose is to determine if using both medications together works better than empagliflozin alone in preventing serious heart-related health issues in people with these three conditions. The study will particularly look at how well this combination prevents death from heart problems and reduces the need for hospital visits due to heart failure.

Participants in this study will receive treatment for about 51 months. During this time, they will take either the combination of both medicines or empagliflozin with a placebo. Their blood pressure, kidney function, and heart health will be monitored throughout the study period. The medications being tested are designed to help manage blood sugar levels and blood pressure while protecting the heart and blood vessels.

Participants will be assigned to receive either olpasiran or a placebo through a subcutaneous injection, which means the medication is delivered into the fatty tissue just under the skin. During the study, researchers will monitor for various health events such as ischemic stroke, which is a blockage of blood flow to the brain, and cardiovascular death. The study will also track changes in the levels of lipoprotein (a) in the blood over time to see how the treatment affects this substance.

Participants in this trial will receive either the study drug, remibrutinib, in the form of a film-coated tablet taken by mouth, or a placebo. The purpose of the study is to determine if this treatment can help delay the progression of disability. During the study, individuals will be monitored over a period of time to observe how the medication affects their physical abilities and overall health.

During the course of this research, participants will receive regular doses of the study drug to observe how it affects the body over an extended period. Medical professionals will monitor various aspects of health, including vital signs such as blood pressure and heart rate, as well as electrocardiogram results, which are tests that record the electrical activity of the heart. Additionally, regular blood tests will be performed to check hematology and clinical chemistry, which are used to examine the components of the blood and the chemical balance in the body.

The purpose of this study is to find out if trimodulin is effective and safe when added to standard care for treating hospitalized adult patients with community-acquired pneumonia or COVID-19 pneumonia. The study will look at whether patients who receive trimodulin do better than those who receive placebo by measuring how many patients get worse or die during the study period. Patients in the study will receive the treatment through an infusion into a vein over five days.

During the study, doctors will monitor patients for up to 91 days to see how they respond to treatment. They will check if patients need more intensive breathing support or if their condition improves, stays the same, or gets worse. The study will also measure various blood markers related to inflammation, immune system function, and blood clotting to understand how the treatment works in the body. Safety will be carefully watched by recording any unwanted effects that occur during and after the treatment period.

The study is divided into two parts, called Part A and Part B. In Part A, researchers will look at changes in the tissue of the intestine after 12 weeks of treatment to see if the disease activity has decreased. In Part B, researchers will check if the treatment can help people achieve clinical remission, which means having no or minimal symptoms of the disease, after 12 weeks of treatment. Participants will receive their assigned treatment and have regular check-ups where doctors will examine their condition. This includes procedures where a flexible tube with a camera is used to look inside the intestine, called endoscopy, and taking small tissue samples to examine under a microscope. Some participants may also be taking corticosteroids, which are medications that reduce inflammation, and they may need to continue or gradually reduce these medications during the study.

Throughout the study, doctors will monitor how the medications are working by checking various signs of the disease. They will measure things like changes in disease scores, improvement in the appearance of the intestine lining, and reduction in symptoms. The study will also track the levels of the study medications in the blood and check if the body develops any immune response to these treatments. Part A will last for 12 weeks, while Part B will continue for up to 48 weeks. The study is expected to start enrolling participants in late 2025 and is planned to be completed by early 2028.

The purpose of the study is to determine how effective REGN7508 is at preventing blood clots after knee replacement surgery when compared to the standard treatments. The medication will be given either through an intravenous injection into a vein or as an injection under the skin. Some patients will receive apixaban tablets to take by mouth, while others will receive enoxaparin as an injection under the skin.

During the study, doctors will monitor patients for signs of blood clots and bleeding. They will also check how well the body tolerates the new medication and whether the body develops any response to it. The study will look for different types of blood clots, including deep venous thrombosis (blood clots in deep veins) and pulmonary embolism (blood clots in the lungs).

The main purpose of this study is to determine if Verekitug can reduce the number of COPD flare-ups (also called exacerbations) that patients experience. During these flare-ups, COPD symptoms become worse than usual, often requiring additional medical treatment. The study will involve patients who have already experienced such flare-ups in the past and are currently using standard COPD medications.

The treatment period will last for 108 weeks (approximately two years). Throughout the study, participants will receive regular injections of either Verekitug or placebo, while continuing their usual COPD medications. The study will monitor how well participants breathe, their quality of life, and any side effects they may experience. Blood samples will be taken to measure how the medication works in the body.

The purpose of this research is to determine how well different doses of SRSD107 work in preventing blood clots compared to enoxaparin in people having knee replacement surgery. During the study, participants will receive either SRSD107 or enoxaparin as injections under the skin. Some participants will also receive sodium chloride solution injections.

The study will monitor participants before their surgery and continue following them for several months afterward. Doctors will check for any signs of blood clots and assess if the medications are working safely. They will use special imaging tests to look for blood clots in the leg that received surgery. The study will also track any bleeding or other health issues that might occur during the treatment period.

The purpose of this research is to assess how safe and well-tolerated NBI-1065845 is when taken as an additional treatment alongside regular antidepressant medication. The study medication comes in the form of oral tablets that participants take along with their current antidepressant treatment.

This is a long-term study that lasts for approximately 52 weeks (one year). During this time, all participants receive the study medication NBI-1065845 while continuing their current antidepressant treatment at the same dose they were taking before joining the study. The study team monitors participants’ health and any side effects that may occur throughout the treatment period.

The study medication comes in the form of film-coated tablets that are taken by mouth once daily. The treatment period lasts up to 76 weeks, during which participants will receive either BI 1291583 at a dose of 2.5 mg or a matching placebo. This is part of what is called a Phase III study, which is one of the final stages of testing a new medication before it can be approved for general use.

Throughout the study, participants will be monitored for improvements in their condition, particularly focusing on how often they experience pulmonary exacerbations (sudden worsening of respiratory symptoms that require antibiotic treatment). The study will also track changes in breathing tests and how the treatment affects participants’ quality of life related to their respiratory symptoms.

The purpose of the study is to see if ferric derisomaltose can help reduce the number of deaths related to heart problems and the number of times patients need to be hospitalized due to worsening heart failure. Participants in the study will be randomly assigned to receive either the iron treatment or no iron treatment. The study will monitor participants over a period of time to track their health outcomes, such as hospital visits and overall survival.

Throughout the study, researchers will collect information on various health indicators, including changes in heart failure symptoms and iron levels in the blood. The study aims to provide valuable insights into whether treating iron deficiency with ferric derisomaltose can improve the health and quality of life for people with Chronic Heart Failure.

The purpose of the study is to evaluate how well olezarsen works in reducing the levels of fasting triglycerides from the start of the study. Participants will receive either olezarsen or a placebo and will be monitored over a period of time to see how their triglyceride levels change. The study will also look at other factors, such as changes in certain proteins and cholesterol levels, and the occurrence of any related health events.

Participants in the study will be required to follow a specific diet and lifestyle, and they will continue their current lipid-lowering therapy, which is a treatment to help manage fat levels in the blood. The study will last for about 53 weeks, during which time participants will have regular check-ups to monitor their health and the effects of the treatment. The goal is to determine if olezarsen can effectively lower triglyceride levels and improve overall health outcomes for those with severe hypertriglyceridemia.

The purpose of the study is to assess the effectiveness and safety of efgartigimod PH20 SC. Participants in the study will receive either the treatment or a placebo. The study will monitor changes in skin condition over a period of time, specifically looking at improvements in skin thickness and overall health. Participants will be observed for any side effects or changes in their health during the study.

The study will last for several months, with regular check-ups to track progress. Participants will have their skin condition assessed at different points in time to see how well the treatment is working. The study aims to provide valuable information on whether efgartigimod PH20 SC can be a beneficial treatment for those living with Systemic Sclerosis.

The purpose of the study is to compare how these two treatments work in the body, their effects on the disease, and their safety. Participants will receive either ABP 692 or Ocrevus, and the study will monitor how the treatments affect the number of new active brain lesions, which are areas of damage in the brain that can be seen using a special imaging technique called MRI (Magnetic Resonance Imaging). The study will last for about 48 weeks, with regular check-ups to assess the treatments’ effects and safety.

Throughout the study, participants will receive regular infusions and undergo various assessments to monitor their health and the progression of their condition. The goal is to determine if ABP 692 is as effective and safe as Ocrevus in treating RRMS. This information could help improve treatment options for people living with this condition.

The purpose of this research is to determine how well sonelokimab works compared to placebo in treating people with active psoriatic arthritis who have not previously used biological medications. The study will compare two different ways of giving sonelokimab against placebo treatment.

Participants will receive either sonelokimab injections or placebo for 16 weeks. The medication dose will be 60 milligrams, given every four weeks. Throughout the study, doctors will monitor the participants’ symptoms, particularly focusing on how their joint pain and inflammation respond to the treatment. The study will also track any changes in participants’ ability to perform daily activities and their overall well-being.

Participants in the study will receive UGN-102 as a primary treatment to see if it can effectively remove the cancer. The study will follow a single-arm design, meaning all participants will receive the same treatment without a comparison group. The treatment period will last for a maximum of six weeks, and the participants will be monitored for any changes in their condition. The study will assess the cancer’s response to the treatment at various points, including three months after the first dose.

Throughout the study, the safety of UGN-102 will be closely monitored by checking for any side effects or adverse reactions. Participants will undergo regular check-ups, including physical exams and laboratory tests, to ensure their well-being. The study aims to provide valuable information on the potential of UGN-102 as a treatment option for patients with low-grade NMIBC, helping to determine if it can effectively reduce or eliminate the cancer while maintaining a good safety profile.

The main purpose of this research is to determine if these medications are safe and well-tolerated by children between 3 months and 12 years of age. During the study, children will receive either ORBACTIV or KIMYRSA as a single treatment. Some participants will also receive aztreonam, another antibiotic given by injection.

The study will track how children respond to the treatment and monitor for any side effects. Doctors will check for signs of infection improvement, such as reduction in skin redness, swelling, and warmth. They will also monitor the children’s overall health status throughout the treatment period, which may last up to 14 days.

The purpose of the study is to evaluate how effective Lu AG09222 is in preventing migraines in adults who have not found relief from previous preventive treatments. The study will involve participants with both episodic and chronic forms of migraine. During the trial, participants will be randomly assigned to different groups, and neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This approach helps ensure that the results are unbiased.

Participants will be monitored over a period of time to track changes in their migraine frequency and severity. The study will also assess the safety of Lu AG09222 by checking for any side effects and changes in health indicators such as vital signs and laboratory test results. The trial aims to provide valuable information on whether this new treatment can offer a new option for people suffering from migraines.

The purpose of the study is to evaluate how effective guselkumab is in improving the signs and symptoms of psoriatic arthritis and to see if it can help slow down the damage to the joints that can be seen on X-rays. Participants in the study will receive either guselkumab or a placebo, which looks like the medication but does not contain the active ingredient. The study will follow participants over a period of time to monitor their response to the treatment.

Throughout the study, participants will receive regular injections and attend scheduled visits to check on their progress. The study aims to provide valuable information on whether guselkumab can be a safe and effective treatment option for people living with active psoriatic arthritis.

The purpose of the study is to determine if BP11 works as well as Xolair in treating patients with this type of chronic hives. Participants in the study will receive either BP11, Xolair, or a placebo, which is an inactive substance. The study will last for several months, during which participants will receive regular injections and attend scheduled visits to monitor their condition and any changes in their symptoms. The study will also assess the safety of the treatments by monitoring any side effects or reactions that may occur.

Throughout the study, participants will be asked to keep a diary of their symptoms and any changes they experience. This information will help researchers understand how well the treatments are working and if there are any differences between them. The study will also involve regular check-ups, including physical exams and laboratory tests, to ensure the safety and well-being of the participants. The ultimate goal is to find an effective treatment option for those who suffer from Chronic Spontaneous Urticaria and have not found relief with current medications.

The purpose of the study is to evaluate the effectiveness and safety of this combination treatment compared to using aflibercept alone. Participants in the study will receive injections directly into the eye, a method known as intravitreal use. The study will last for a period of 96 weeks, during which participants will receive regular injections and have their vision monitored to assess any changes.

Throughout the study, some participants will receive a placebo, which is a treatment that looks like the real medication but does not contain any active ingredients. This helps researchers understand the true effects of the medications being tested. The study will measure changes in vision and other eye health indicators to determine the success of the treatment. The goal is to find out if the combination of OPT-302 and aflibercept can provide better results for people with wet AMD.

The purpose of the study is to see if the new combination of domvanalimab and zimberelimab with chemotherapy can help people live longer compared to the treatment with nivolumab and chemotherapy. Participants in the study will be randomly assigned to receive either the new combination treatment or the nivolumab treatment. The study will last for up to 24 months, during which participants will receive their assigned treatment and be monitored regularly by the study team. The study will also look at how the treatments affect the participants’ quality of life and any side effects they may experience.

In addition to the main goal of comparing how long participants live with each treatment, the study will also look at other important factors. These include how long it takes for the cancer to start growing again, how many participants experience a reduction in their cancer size, and how long these reductions last. The study will also monitor any side effects or adverse events that participants may experience during the trial. This information will help researchers understand the safety and effectiveness of the new treatment combination.